Oral vaccination: Where we are?

Expert Opinion on Drug Delivery

Volumn 4, Issue 4, 2007, Pages 323-340

  Silin, Dmytro S ^a   Lyubomska, Oksana K ^a   Jirathitikal, Vichai ^a   Bourinbaiar, Aldar S ^b  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b Immunitor USA Inc   (United States)

Author keywords

Immunotherapy; Mucosal vaccination; Native immunity; Oral tolerance; Vaccine delivery

Indexed keywords

ALVAKOL; BACTERIAL VACCINE; BIOMUNIL; BIOSTIM; CHOLERA VACCINE; DIPHTHERIA PERTUSSIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B VACCINE; GRASS POLLEN VACCINE; GRAZAX GRASS POLLEN VACCINE; IMOCUR; INACTIVATED VACCINE; INFLUENZA VACCINE; ISCOM; ISMIGEN; KANVAKOL; LIPOSOME; LUIVAC; MICROSPHERE; NIOSOME; OM 85; PASPAT; POLIOMYELITIS VACCINE; POLYETHYLENE; POLYSTYRENE; RABIES VACCINE; RESPIVAX; RIBOMUNYL; ROTAVIRUS VACCINE; TYPHOID VACCINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; URVAKOL; VACCINE; VAXIHALER FLU; VIROSOME;

ARAB; CHINA; COW; DESERT; FLEA; HUMAN; IMMUNIZATION; MEAT; NONHUMAN; RABIES; REVIEW; SMALLPOX; TUBERCULOSIS; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, ORAL; ANIMALS; CHEMISTRY, PHARMACEUTICAL; DRUG CARRIERS; DRUG COMPOUNDING; GASTROINTESTINAL TRACT; HUMANS; IMMUNE TOLERANCE; IMMUNITY, MUCOSAL; VACCINATION; VACCINES, ATTENUATED; VACCINES, EDIBLE; VACCINES, INACTIVATED;

EID: 34547881948     PISSN: 17425247     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425247.4.4.323     Document Type: Review

References (183)

1. TADJBAKHSH H: In: History of Human and Veterinary Medicine in Iran. Fondation Merieux, Lyon (2003).
2. SILIN DS, LIAO CW, LYUBOMSKA OV, WENG CN: Immunity development following oral vaccination against Actinobacillus pleuropneumoniae in a mouse model. Int. J. Biotechnol. (2007) (In Press).
3. BOURINBAIAR AS, METADILOGKUL O, JIRATHITIKAL V: Mucosal AIDS vaccines. Viral Immunol. (2003) 16:427-445.
4. TAKAHASHI I, KIYONO H: Gut as the largest immunologic tissue. J. Parenter. Enteral Nutr. (1999) 23(5 Suppl.):S7-S12.
5. PABST R, ROSENBERG YJ: Interpreting data on lymphocyte subsets in the blood of HIV patients - organ distribution, proliferation and migration kinetics are critical factors. Pathobiology (1998) 66(3-4):117-122.
6. HOLMGREN J, CZERKINSKY C, LYCKE N, SVENNERHOLM AM: Mucosal immunity implications for vaccine development. Immunobiology (1992) 184(2-3):157-179.
7. MAYER L: Mucosal immunity and gastrointestinal antigen processing. J. Pediatr. Gastroenterol. Nutr. (2000) 30(Suppl.):S4-S12.
8. KERNEIS S, BOGDANOVA A, KRAEHENBUHL JP, PRINGAULT E: Conversion by Peyer's patch lymphocytes of human enterocytes into M cells that transport bacteria. Science (1997) 277(5328):949-952.
9. BELLON G, OUNIS I: The preventive treatment of recurring respiratory infections using RU 41740 in 3,008 children. Ann. Pediatr. (Paris) (1990) 37(8):535-540.
10. PAUPE J: Value of Imocur in the prevention of recurrent infections in children under six years of age. Results of a multicenter, placebo-controlled trial. Ann. Pediatr. (Paris) (1990) 37(7):475-479.
11. RUTISHAUSER M, PITZKE P, GREVERS G et al.: Use of a polyvalent bacterial lysate in patients with recurrent respiratory tract infections: results of a prospective, placebo-controlled, randomized, double-blind study. Adv. Ther. (1998) 15(6):330-341.
12. SERRANO F, DEMANEZ JP, MORGON A, CHASTANG C, VAN CAUWENBERGE P: Effectiveness of ribosomal fractions of Klebsiella pneumoniae, Streptococcus pneumoniae, Streptococcus pyogenes, Haemophilus influenzae and the membrane fraction of Kp (Ribomunyl) in the prevention of clinical recurrences of infectious rhinitis. Results of a multicenter double-blind placebocontrolled study. Eur. Arch Otorhinolaryngol. (1997) 254(8):372-375.
13. TRACH DD, CLEMENS JD, KE NT et al.: Field trial of a locally produced, killed, oral cholera vaccine in Vietnam. Lancet (1997) 349(9047):231-235.
14. HAMAJIMA K, SASAKI S, FUKUSHIMA J et al.: Intranasal administration of HIV-DNA vaccine formulated with a polymer, carboxymethylcellulose, augments mucosal antibody production and cell-mediated immune response. Clin. Immunol. Immunopathol. (1998) 88(2):205-210.
15. MANNINO RJ, CANKI M, FEKETEOVA E et al.: Targeting immune response induction with cochleate and liposome-based vaccines. Adv. Drug Deliv. Rev. (1998) 32(3):273-287.
16. SAKAUE G, HIROI T, NAKAGAWA Y et al.: HIV mucosal vaccine: nasal immunization with gp160-encapsulated hemagglutinating virus of Japan-liposome induces antigen-specific CTLs and neutralizing antibody responses. J. Immunol. (2003) 170(1):495-502.
17. SINGH M, VAJDY M, GARDNER J, BRIONES M, O'HAGAN D: Mucosal immunization with HIV-1 gag DNA on cationic microparticles prolongs gene expression and enhances local and systemic immunity. Vaccine (2001) 20(3-4):594-602.
18. RYDELL N, STERTMAN L, STALENHEIM G, SJOHOLM I: Use of an oral diphtheria vaccine in human. Vaccine (2006) 24(33-34):5928-5930.
19. MITTAL SK, AGGARWAL N, SAILAJA G et al.: Immunization with DNA, adenovirus or both in biodegradable alginate microspheres: effect of route of inoculation on immune response. Vaccine (2000) 19(2-3):253-263.
20. RAJKANNAN R, DHANARAJU MD, GOPINATH D, SELVARAJ D, JAYAKUMAR R: Development of hepatitis B oral vaccine using B-cell epitope loaded PLG microparticles. Vaccine (2006) 24(24):5149-5157.
21. MOSER C, METCALF IC, VIRET JF: Virosomal adjuvanted antigen delivery systems. Expert Rev. Vaccine (2003) 2:189-196.
22. CHALLACOMBE SJ, RAHMAN D, JEFFERY H, DAVIS SS, O'HAGAN DT: Enhanced secretory IgA and systemic IgG antibody responses after oral immunization with biodegradable microparticles containing antigen. Immunology (1992) 76(1):164-168.
23. KATZ DE, DELORIMIER AJ, WOLF MK et al.: Oral immunization of adult volunteers with microencapsulated enterotoxigenic Escherichia coli (ETEC) CS6 antigen. Vaccine (2003) 21(5-6):341-346.
24. KANEKO H, BEDNAREK I, WIERZBICKI A et al.: Oral DNA vaccination promotes mucosal and systemic immune responses to HIV envelope glycoprotein. Virology (2000) 267(1):8-16.
25. HERRMANN JE, CHEN SC, JONES DH et al.: Immune responses and protection obtained by oral immunization with rotavirus VP4 and VP7 DNA vaccines encapsulated in microparticles. Virology (1999) 259(1):148-153.
26. HUANG W, BAI Y, WANG JD et al.: Preparation oral liposome-encapsulated recombinant Helicobacter pylori heat shock protein 60 vaccine for prevention of Hp infection. Di Yi. Jun. Yi. Da. Xue. Xue. Bao. (2005) 25(5):531-534.
27. TANA, WATARAI S, ISOGAI E, OGUMA K: Induction of intestinal IgA and IgG antibodies preventing adhesion of verotoxin-producing Escherichia coli to Caco-2 cells by oral immunization with liposomes. Lett. Appl. Microbiol. (2003) 36(3):135-139.
28. MIRCHAMSY H, MANHOURI H, HAMEDI M et al.: Stimulating role of toxoids-laden liposomes in oral immunization against diphtheria and tetanus infections. Biologicals (1996) 24(4):343-350.
29. KAZANJI M, LAURENT F, PERY P: Immune responses and protective effect in mice vaccinated orally with surface sporozoite protein of Eimeria falciformis in ISCOMs. Vaccine (1994) 12(9):798-804.
30. IOSEF C, VAN NGUYEN T, JEONG K et al.: Systemic and intestinal antibody secreting cell responses and protection in gnotobiotic pigs immunized orally with attenuated Wa human rotavirus and Wa 2/ 6-rotavirus-like-particles associated with immunostimulating complexes. Vaccine (2002) 20(13-14):1741-1753.
31. BABIUK S, BACA-ESTRADA ME, MIDDLETON DM et al.: Biphasic lipid vesicles (Biphasix) enhance the adjuvanticity of CpG oligonucleotides following systemic and mucosal administration. Curr. Drug Deliv. (2004) 1(1):9-15.
32. FOSTER N, CLARK MA, JEPSON MA, HIRST BH: Ulex europaeus 1 lectin targets microspheres to mouse Peyer's patch M-cells in vivo. Vaccine (1998) 16(5):536-541.
33. SHARMA R, VAN DAMME EJ, PEUMANS WJ, SARSFIELD P, SCHUMACHER U: Lectin binding reveals divergent carbohydrate expression in human and mouse Peyer's patches. Histochem. Cell Biol. (1996) 105(6):459-465.
34. GIANNASCA PJ, GIANNASCA KT, LEICHTNER AM, NEUTRA MR: Human intestinal M cells display the sialyl Lewis A antigen. Infect. Immunol. (1999) 67(2):946-953.
35. KODAMA C, EGUCHI M, SEKIYA Y et al.: Evaluation of the Lon-deficient Salmonella strain as an oral vaccine candidate. Microbiol. Immunol. (2005) 4(12):1035-1045.
36. WAHID R, SALERNO-GONCALVES R, TACKET CO, LEVINE MM, SZTEIN MB: Cell-mediated immune responses in humans after immunization with one or two doses of oral live attenuated typhoid vaccine CVD 909. Vaccine (2007) 25(8):1416-1425.
37. KIRKPATRICK BD, MCKENZIE R, O'NEILL JP et al.: Evaluation of Salmonella enterica serovar Typhi (Ty2 aroC-ssaV-) M01ZH09, with a defined mutation in the Salmonella pathogenicity island 2, as alive, oral typhoid vaccine in human volunteers. Vaccine (2006) 2(2):116-123.
38. HYLAND KA, BROWN DR, MURTAUGH MP: Salmonella enterica serovar Choleraesuis infection of the porcine jejunal Peyer's patch rapidly induces IL-1β and IL-8 expression. Vet. Immunol. Immunopathol. (2006) 109(1-2):1-11.
39. GANTOIS I, DUCATELLE R, TIMBERMONT L et al.: Oral immunisation of laying hens with the live vaccine strains of TAD Salmonella vac E and TAD Salmonella vac T reduces internal egg contamination with Salmonella Enteritidis. Vaccine (2006) 24(37-39):6250-6255.
40. WIGLEY P, HULME S, POWERS C et al.: Oral infection with the Salmonella enterica serovar Gallinarum 9R attenuated live vaccine as a model to characterise immunity to fowl typhoid in the chicken. BMC Vet. Res. (2005) 1:2.
41. RAGOT C, GARNOTEL E, VEDY S, MORILLON M: Dukoral, oral cholera vaccine Dukoral, vaccin oral contre le cholera. Med. Trop. (Mars.) (2006) 6(3):237-239.
42. ANH DD, CANH DC, LOPEZ AL et al.: Safety and immunogenicity of a reformulated Vietnamese bivalent killed, whole-cell, oral cholera vaccine in adults. Vaccine (2007) 25(6):1149-1155.
43. QADRI F, CHOWDHURY MI, FARUQUE SM et al.: Peru-15, a live attenuated oral cholera vaccine, is safe and immunogenic in Bangladeshi toddlers and infants. Vaccine (2007) 25(2):231-238.
44. LIANG W, WANG S, YU F et al.: Construction and evaluation of a safe, live, oral Vibrio cholerae vaccine candidate, IEM 108. Infect. Immunol. (2003) 71(10):5498-5504.
45. QADRI F, AHMED T, AHMED F et al.: Reduced doses of oral killed enterotoxigenic Eccherichia coli plus cholera toxin B subunit vaccine is safe and immunogenic in Bangladeshi infants 6-17 months of age: dosing studies in different age groups. Vaccine (2006) 24(10):1726-1733.
46. MAYR UB, HALLER C, HAIDINGER W et al.: Bacterial ghosts as an oral vaccine: a single dose of E. coli O157:H7 bacterial ghosts protects mice against lethal challenge. Infect. Immunol. (2005) 7(8):4810-4817.
47. + E. coli oral vaccine in stimulating ileal Peyer's patch T cells in weaned pigs. J. Vet. Pharmacol. Ther. (2006) 29(3):199-204.
48. HUSSAIN N, FLORENCE AT: Utilizing bacterial mechanisms of epithelial cell entry: invasin induced oral uptake of latex nanoparticles. Pharm. Res. (1998) 15:153-156.
49. BAUMLER AJ, TSOLIS RM, HEFFRON F: The lpf fimbrial operon mediates adhesion of Salmonella typhimurium to murine Peyer's patches. Proc. Natl. Acad. Sci. USA (1996) 93(1):279-283.
50. HAROKOPAKIS E, HAJISHENGALLIS G, MICHALEK SM: Effectiveness of liposomes possessing surface-linked recombinant B subunit of cholera toxin as an oral antigen delivery system. Infect. Immunol. (1998) 66(9):4299-4304.
51. LEE SH, MIZUTANI N, MIZUTANI M et al.: Endoglin (CD105) is a target for an oral DNA vaccine against breast cancer. Cancer Immunol. Immunother. (2006) 55(12):1565-1574.
52. CHOU CK, HUNG JY, LIU JC, CHEN CT, HUNG MC: An attenuated Salmonella oral DNA vaccine prevents the growth of hepatocellular carcinoma and colon cancer that express alphafetoprotein. Cancer Gene Ther. (2006) 13(8):746-752.
53. MENG FP, DING J, YU ZC et al.: Oral attenuated Salmonella typhimurium vaccine against MG7-Ag mimotope of gastric cancer. World J. Gastroenterol. (2005) 11(12):1833-1836.
54. VRTALA S, GROTE M, FERREIRA F et al.: Humoral immune responses to recombinant tree pollen allergens (Bet v I and Bet v II) in mice: construction of a live oral allergy vaccine. Int. Arch. Allergy Immunol. (1995) 107(1-3):290-294.
55. CHEN Y, HELMUS R, MCCLANE B et al.: Use of a clostridium perfringens vector to express high levels of SIV p27 protein for the development of an oral SIV vaccine. Virology (2004) 329(2):226-233.
56. ZHAO X, ZHANG M, LI Z, FRANKEL FR: Vaginal protection and immunity after oral immunization of mice with a novel vaccine strain of Listeria monocytogenes expressing human immunodeficiency virus type 1 gag. J. Virol. (2006) 80(18):8880-8890.
57. NEESON P, BOYER J, KUMARS et al.: A DNA prime-oral Listeria boost vaccine in rhesus macaques induces a SIV-specific CD8 T cell mucosal response characterized by high levels of α4β7 integrin and an effector memory phenotype. Virology (2006) 354(2):299-315.
58. RYAN ET, CREAN TI, JOHN M et al.: In vivo expression and immunoadjuvancy of a mutant of heat-labile enterotoxin of E. coli in vaccine and vector strains of Vibrio cholerae. Infect. Immunol. (1999) 67(4):1694-1701.
59. KOPROWSKI H, LEVINE MM, ANDERSON RJ et al.: Attenuated Shigella flexneri 2a vaccine strain CVD 1204 expressing colonization factor antigen I and mutant heat-labile enterotoxin of enterotoxigenic E. coli. Infect. Immunol. (2000) 68(9):4884-4892.
60. O'GAORA P, ROBERTS M, BOWE F et al.: Yersinia enterocolitica aroA mutants as carriers of the B subunit of the E. coli heat-labile enterotoxin to the murine immune system. Microb. Pathog. (1990) 9(2):105-116.
61. KAWAHARA M, HASHIMOTO A, TOIDA I, HONDA M: Oral recombinant Mycobacterium bovis bacillus Calmette-Guerin expressing HIV-1 antigens as a freeze-dried vaccine induces long-term, HIV-specific mucosal and systemic immunity. Clin. Immunol. (2002) 105(3):326-331.
62. KOTLOFF KL, WASSERMAN SS, JONES KF et al.: Clinical and microbiological responses of volunteers to combined intranasal and oral inoculation with a Streptococcus gordonii carrier strain intended for future use as a group A streptococcus vaccine. Infect. Immunol. (2005) 73(4):236-236.
63. RAHA AR, VARMA NR, YUSOFF K, ROSS E, FOO HL: Cell surface display system for Lactococcus lactis: a novel development for oral vaccine. Appl. Microbiol. Biotechnol. (2005) 68(1):75-81.
64. WOLF JL, KAUFFMAN RS, FINBERG R et al.: Determinants of reovirus interaction with the intestinal M cells and absorptive cells of murine intestine. Gastroenterology (1983) 85(2):291-300.
65. RUBAS W, BANERJEA AC, GALLATI H, SPEISER PP, JOKLIK WK: Incorporation of the reovirus M cell attachment protein into small unilamellar vesicles: incorporation efficiency and binding capability to L929 cells in vitro. J. Microencapsul. (1990) 7(3):385-395.
66. HUTCHINGS AB, HELANDER A, SILVEY KJ et al.: Secretory immunoglobulin A antibodies against the sigmal outer capsid protein of reovirus type 1 Lang prevent infection mouse Peyer's parches. J. Virol. (2004) 78(2):947-957.
67. HELANDER A, SILVEY KJ, MANTIS NJ et al.: The viral sigma 1 protein and glycoconjugates containing α2-3-linked sialic acid are involved in type 1 reovirus adherence to M cell apical surfaces. J. Virol. (2003) 77(14):7964-7977.
68. XIANG ZQ, GAO GP, REYES-SANDOVAL A et al.: Oral vaccination of mice with adenoviral vectors is not impaired by preexisting immunity to the vaccine carrier. J. Virol. (2003) 77(20):10780-10789.
69. HARA H, MONSONEGO A, YUASA K et al.: Development of a safe oral Aβ vaccine using recombinant adeno-associated virus vector for Alzheimer's disease. J. Alzheimers Dis. (2004) 6(5):483-488.
70. SCHECKELHOFF MR, TELFORD SR, HU LT: Protective efficacy of an oral vaccine to reduce carriage of Borrelia burgdorferi (strain N40) in mouse and tick reservoirs. Vaccine (2006) 24(11):1949-1957.
71. ALLWRIGHT S, BRADLEY F, LONG J et al.: Prevalence of antibodies to hepatitis B, hepatitis C, and HIV and risk factors in Irish prisoners: results of a national cross sectional survey. BMJ (2000) 321(7253):78-82.
72. WIMSATT J, BIGGINS D, INNES K, TAYLOR B, GARELL D: Evaluation of oral and subcutaneous delivery of an experimental canarypox recombinant canine distemper vaccine in the Siberian polecat (Mustela eversmanni). J. Zoo Wildl. Med. (2003) 34(1):25-35.
73. TAKAMURA S, NIIKURA M, LI TC et al.: DNA vaccine-encapsulated virus-like particles derived from an orally transmissible virus stimulate mucosal and systemic immune responses by oral administration. Gene Ther. (2004) 11(7):628-635.
74. NIIKURA M, TAKAMURA S, KIM G et al.: Chimeric recombinant hepatitis E virus-like particles as an oral vaccine vehicle presenting foreign epitopes. Virology (2002) 293(2):273-280.
75. ZURBRIGGEN R, GLUCK R: Immunogenicity of IRIV- versus alum-adjuvanted diphtheria and tetanus toxoid vaccines in influenza primed mice. Vaccine (1999) 17(11-12):1301-1305.
76. CUSI MG, DEL VECCHIO MT, TERROSI C et al.: Immune-reconstituted influenza virosome containing CD40L gene enhances the immunological and protective activity of a carcinoembryonic antigen anticancer vaccine. J. Immunol. (2005) 174(11):7210-7216.
77. HUANG H, WU P, TEO C et al.: Improved immunogenicity of a self tumor antigen by covalent linkage to CD40 ligand. Int. J. Cancer (2004) 108(5):696-703.
78. LI Q, GAO JQ, QIU LY, CUI FD, JIN Y: Enhanced immune responses induced by vaccine using Sendai virosomes as carrier. Int. J. Pharm. (2007) 329(1-2):117-121.
79. KAPCZYNSKI DR: Development of a virosome vaccine against avian metapneumovirus subtype C for protection in turkeys. Avian Dis. (2004) 48(2):332-343.
80. SHOJI J,TANIHARA Y, UCHIYAMA T, KAWAI A: Preparation of virosomes coated with the vesicular stamatitis virus glycoprotein as efficient gene transfer vehicles for animal cells. Microbiol. Immunol. (2004) 48(3):163-174.
81. VRUBLEVSKAIA VV, VINOKUROV MG, KHOLODKOV OA, KORNEV AN, MORENKOV OS: Incorporation of glycoproteins of the Aujeszky's disease virus (Suid herpesvirus 1) into artificial liposome membranes and their interaction with cells. Vopr. Virusol. (2004) 49(2):32-36.
82. HOMHUAN A, PRAKONGPAN S, POOMVISES P et al.: Virosome and ISCOM vaccines against Newcastle disease: preparation, characterization and immunogenicity. Eur. J. Pharm. Sci. (2004) 22(5):459-468.
83. ZURBRIGGEN R: Immunostimulating reconstituted influenza virosomes. Vaccine (2003) 21(9-10):921-924.
84. RIEDEMANN S, REINHARDT G, IBARRA H, FROSNER GG: Immunogenicity and safety of a virosomal hepatitis A vaccine (Epaxal) in healthy toddlers and children in Chile. Acta Paediatr. (2004) 93(3):412-414.
85. MOSER C, METCALFE IC, VIRET JF: Virosomal adjuvanted antigen delivery systems. Expert Rev. Vaccines (2003) 2(2):189-196.
86. LAMBKIN R, OXFORD JS, BOSSUYT S et al.: Strong local and systemic protective immunity induced in the ferret model by an intranasal virosome-formulated influenza subunit vaccine. Vaccine (2004) 22(31-32):4390-4396.
87. CUSI MG, TERROSI C, SAVELLINI GG et al.: Efficient delivery of DNA to dendritic cells mediated by influenza virosomes. Vaccine (2004) 22(5-6):735-739.
88. CUSI MG, ZURBRIGGEN R, VALASSINA M et al.: Intranasal immunization with mumps virus DNA vaccine delivered by influenza virosomes elicits mucosal and systemic immunity. Virology (2000) 277(1):111-118.
89. JAIN S, VYAS SP: Mannosylated niosomes as adjuvant-carrier system for oral mucosal immunization. J. Liposome Res. (2006) 16(4):331-345.
90. SINGH P, PRABAKARAN D, JAIN S et al.: Cholera toxin B subunit conjugated bile salt stabilized vesicles (biosomes) for oral immunization. Int. J. Pharm. (2004) 278(2):379-390.
91. LELOUARD H, REGGIO H, MANGEAT P, NEUTRA M, MONTCOURRIER P: Mucinrelated epitopes distinguish M cells and enterocytes in rabbit appendix and Peyer's patches. Infect. Immunol. (1999) 67(1):357-367.
92. WELTZIN R, LUCIA-JANDRIS P, MICHETTI P et al.: Binding and transepithelial transport of immunoglobulins by intestinal M cells: demonstration using monoclonal IgA antibodies against enteric viral proteins. J. Cell Biol. (1989) 108(5):1673-1685.
93. VELEZ CN, TONKONOGY SL, LICHTMAN SN, CHO MJ: Sensitized liposomes as an antigen delivery system for the stimulation of mucosal immunity. J. Drug Target (1997) 5(1):15-24.
94. PAPPO J, ERMAK TH, STEGER HJ: Monoclonal antibody-directed targeting of fluorescent polystyrene microspheres to Peyer's patch M cells. Immunology (1991) 73(3):277-280.
95. STEPHENSON I, ZAMBON MC, RUDINA et al.: Phase I evaluation of intranasal trivalent inactivated influenza vaccine with nontoxigenic E. coli enterotoxin and novel biovector as mucosal adjuvants, using adult volunteers. J. Virol. (2006) 80(10):4962-4970.
96. KENDE M, DEL GIUDICE G, RIVERA N, HEWETSON J: Enhancement of intranasal vaccination in mice with deglycosylated chain A ricin by LTR72, a novel mucosal adjuvant. Vaccine (2006) 24(12):2213-2221.
97. MELKEBEEK V, SONCK E, VERDONCK F, GODDEERIS BM, COX E: Optimized FaeG expression and a thermolabile enterotoxin DNA adjuvant enhance priming of an intestinal immune response by an FaeG DNA vaccine in pigs. Clin. Vaccine Immunol. (2007) 14(1):28-35.
98. KLEANTHOUS H, MYERS GA, GEORGAKOPOULOS KM et al.: Rectal and intranasal immunizations with recombinant urease induce distinct local and serum immune responses in mice and protect against Helicobacter pylori infection. Infect. Immunol. (1998) 66(6):2879-2886.
99. DUNN LA, MCMILLAN DJ, BATZLOFF M et al.: Parenteral and mucosal delivery of a novel multi-epitope M protein-based group A streptococcal vaccine construct investigation of immunogenicity in mice. Vaccine (2002) 20(21-22):2635-2640.
100. SONG H, WANG Z, ZHENG D et al.: A novel mucosal vaccine against foot-and-mouth disease virus induces protection in mice and swine. Biotechnol. Lett. (2005) 27(21)1669-1674.
101. GONG ZH, JIN HQ, JIN YF, ZHANG YZ: Expression of cholera toxin B subunit and assembly as functional oligomers in silkworm. J. Biochem. Mol. Biol. (2005) 38(6):717-724.
102. CONG H, GU QM, JIANG Y et al.: Oral immunization with a live recombinant attenuated Salmonella typhimurium protects mice against Toxoplasma gondii Parasite Immunol. (2005) 27(1-2):29-35.
103. ANDERSEN CS, DIETRICH J, AGGER EM et al.: The combined CTA1-DD/ ISCOMs vector is an effective intranasal adjuvant for boosting prior Mycobacterium bovis BCG immunity to Mycobacterium tuberculosis. Infect. Immunol. (2007) 75(1):408-416.
104. GRDIC D, SMITH R, DONACHIE A et al.: The mucosal adjuvant effects of cholera toxin and immune-stimulating complexes differ in their requirement for IL-12, indicating different pathways of action. Eur. J. Immunol. (1999) 29(6):1774-1784.
105. ROSAS G, FRAGOSO G, AINCIART N et al.: Brucella spp. lumazine synthase: a novel adjuvant and antigen delivery system to effectively induce oral immunity. Microbes Infect. (2006) 8(5)1277-1286.
106. KAMINSKI RW, TURBYFILL KR, OAKS EV: Mucosal adjuvant properties of the Shigella invasin complex. Infect. Immunol. (2006) 74(5):2856-2866.
107. DUVERGER A, JACKSON RJ, VAN GINKEL FW et al.: Bacillus anthracis edema toxin acts as an adjuvant for mucosal immune responses to nasally administered vaccine antigens. J. Immunol. (2006) 176(3):1776-1783.
108. LEE SE, KIM SY, JEONG BC et al.: A bacteria] flagellin, Vibrio vulnificus FlaB, has a strong mucosal adjuvant activity to induce protective immunity Infect. Immunol. (2006) 74(1):694-702.
109. VAN DE VERG LL, HARTMAN AB, BHATTACHARJEE AK et al.: Outer membrane protein of Neisseria meningitidis as a mucosal adjuvant for lipopolysaccharide of Brucella melitensis in mouse and guinea pig intranasal immunization models. Infect. Immunol. (1996) 64(12):5263-5268.
110. CHABOT S, BREWER A, LOWELL G et al.: A novel intranasal protollin-based measles vaccine induces mucosal and systemic neutralizing antibody responses and cell-mediated immunity in mice, Vaccine (2005) 23(11):1374-1383.
111. BORSUTZKY S, EBENSEN T, LINK C et al.: Efficient systemic and mucosal responses against the HIV-1 Tat protein by prime/boost vaccination using the lipopeptide MALP-2 as adjuvant. Vaccine (2006) 24(12):2049-2056.
112. OLIVE C, SCHULZE K, SUN HK et al.: Enhanced protection against Streptococcus pyogenes infection by intranasal vaccination with a dual antigen component M protein/SfbI lipid core peptide vaccine formulation. Vaccine (2007) 25(10):1789-1797.
113. SLOAT BR, CUI Z: Nasal immunization with anthrax protective antigen protein adjuvanted with polyriboinosinic-polyribocytidylic acid induced strong mucosal and systemic immunities. Pharm. Res. (2006) 23(6):1217-1226.
114. SLOAT BR, CUI Z: Nasal immunization with a dual antigen anthrax vaccine induced strong mucosal and systemic immune responses against toxins and bacilli. Vaccine (2006) 24(40-41):6405-6413.
115. TENGVALL S, LUNDQVIST A, EISENBERG RJ, COHEN GH, HARANDI AM: Mucosal administration of CpG oligodeoxynucleotide elicits strong CC and CXC chemokine responses in the vagina and serves as a potent Th1-tilting adjuvant for recombinant gD2 protein vaccination against genital herpes. J. Virol. (2006) 80(11):5283-5291.
116. ZUERCHER AW, HORN MP, WU H et al.: Intranasal immunisation with conjugate vaccine protects mice from systemic and respiratory tract infection with Pseudomonas aeruginosa. Vaccine (2006) 24(20):4333-4342.
117. ABE N, KODAMA S, HIRANO T, ETO M, SUZUKI M: Nasal vaccination with CpG oligodeoxynucleotide induces protective immunity against non-typeable Haemophilus influenzae in the nasopharynx. Laryngoscope (2006) 116(3):407-412.
118. KODAMA S, ABE N, HIRANO T, SUZUKI M: Safety and efficacy of nasal application of CpG oligodeoxynucleotide as a mucosal adjuvant. Laryngoscope (2006) 116(2):331-335.
119. MCCLUSKIE MJ, DAVIS HL: Oral, intrarectal and intranasal immunizations using CpG and non-CpG oligodeoxynucleotides as adjuvants. Vaccine (2000) 19(4-5):413-422.
120. ALDERSON MR, MCGOWAN P, BALDRIDGE JR, PROBST P: TLR4 agonists as immunomodulatory agents. J. Endotoxin Res. (2006) 12(5):313-319.
121. BRACCI L, CANINI I, VENDITTI M et al.: Type I IFN as a vaccine adjuvant for both systemic and mucosa] vaccination against influenza virus. Vaccine (2006) 24(Suppl. 2):S2-S7.
122. SABIROV A, METZGER DW: Intranasal vaccination of neonatal mice with polysaccharide conjugate vaccine for protection against pneumococcal otitis media. Vaccine (2006) 24(27-28):5584-5592.
123. MARINARO M, BOYAKA PN, FINKELMAN FD et al.: Oral but not parenteral interleukin (IL)-12 redirects T helper 2 (Th2)-type responses to an oral vaccine without altering mucosa] IgA responses. J. Exp. Med. (1997) 185(3):415-427.
124. WILLIAMSON E, WESTRICH GM, VINEY JL: Modulating dendritic cells to optimize mucosal immunization protocols. J. Immunol. (1999) 163(7):3668-3675.
125. NOUR EL-DIN AN, SHKRETA L, TALBOT BG, DIARRA MS, LACASSE P: DNA immunization of dairy cows with the clumping factor A of Staphylococcus aureus. Vaccine (2006) 24(12):1997-2006.
126. SHAO W, LI X, LI M et al.: Macrophage inflammatory protein-1α expression plasmid enhances DNA vaccine-induced immune responses against HSV-2. Immunol. Cell Biol. (2005) 83(6):626-631.
127. LAVELLE EC, GRANT G, PUSZTAI A et al.: Mistletoe lectins enhance immune responses to intranasally co-administered herpes simplex virus glycoprotein D2. Immunology (2002) 107(2):268-274.
128. LAVELLE EC, GRANT G, PUSZTAI A, PFULLER U, O'HAGAN DT: The identification of plant lectins with mucosal adjuvant activity. Immunology (2001) 102(1):77-86.
129. BOYAKA PN, MARINARO M, JACKSON RJ et al.: Oral QS-21 requires early IL-4 help for induction of mucosal and systemic immunity. J. Immunol. (2001) 166(4):2283-2290.
130. KERSTEN GFA, CROMMELIN DJA: Liposomes and ISCOMs. Vaccine (2003) 21(9-10):915-920.
131. ZHANG P, YANG QB, MARCIANI DJ et al.: Effectiveness of the quillaja saponin semisynthetic analog GPI-0100 in potentiating mucosal and systemic responses to recombinant HagB from Porphyromonas gingivalis. Vaccine (2003) 21(27-30):4459-4471.
132. ATKINSON HA, JOHNSON IT, GEE JM, GRIGORIADOU F, MILLER K: Brown Norway rat model of food allergy effect of plant components on the development of oral sensitization. Food Chem. Toxicol. (1996) 34(1):27-32.
133. CHAVALI SR, BARTON LD, CAMPBELL JB: Immunopotentiation by orally-administered Quillaja saponins: effects in mice vaccinated intraperitoneally against rabies. Clin. Exp. Immunol. (1988) 74(3):339-343.
134. ESTRADA A, LI B, LAARVELD B: Adjuvant action of Chenopodium quinoa saponins on the induction of antibody responses to intragastric and intranasal administered antigens in mice Comp. Immunol. Microbiol. Infect. Dis. (1998) 21(3):225-236.
135. PICKERING RJ, SMITH SD, STRUGNELL RA, WESSELINGH SL, WEBSTER DE: Crude saponins improve the immune response to an oral plant-made measles vaccine. Vaccine (2006) 24(2):144-150.
136. NAGAI T, SUZUKI Y, KIYOHARA H et al.: Onjisaponins, from the root of Polygala tenuifolia Willdenow, as effective adjuvants for nasal influenza and diphtheria-pertussis-tetanus vaccines. Vaccine (2001) 19(32):4824-4834.
137. POPOV SV, GOLOVCHENKO VV, OVODOVA RG et al.: Characterisation of the oral adjuvant effect of lemnan, a pectic polysaccharide of Lemna minor L. Vaccine (2006) 24(26):5413-5419.
138. ISRAF DA, LAJIS NH, SOMCHIT MN, SULAIMAN MR: Enhancement of ovalbuminspecific IgA responses via oral boosting with antigen co-administered with an aqueous Solanum torvum extract. Life Sci. (2004) 75(4):397-406.
139. MEDINA-BOLIVAR F, WRIGHT R, FUNK V et al.: A non-toxic lectin for antigen delivery of plant-based mucosal vaccines. Vaccine (2003) 21(9-10):997-1005.
140. TRAIDL-HOFFMANN C, MARIANI V, HOCHREIN H et al.: Pollen-associated phytoprostanes inhibit dendritic cell interleukin-12 production and augment T helper type 2 cell polarization. J. Exp. Med. (2005) 201(4):627-636.
141. SCHENK R: Combination preparations of botanical extracts as adjuvants in oral mucosal defense. Zahnarztl. Prax. (1988) 39(8):290-297.
142. ABDEL-SALAM OM, BAIUOMY AR, EL BATRAN S, ARBID MS: Evaluation of the anti-inflammatory, anti-nociceptive and gastric effects of Ginkgo biloba in the rat. Pharmacol. Res. (2004) 49(2):133-142.
143. MANABE M,TAKENAKA R, NAKASA T, OKINAKA O: Induction of anti-inflammatory responses by dietary Momordica charantia L. (bitter gourd). Biosci. Biotechnol. Biochem. (2003) 67(12):2512-2517.
144. KIM TG, GRUBER A, RUPRECHT RM, LANGRIDGE WH: Synthesis and assembly of SIVmac Gag p27 capsid protein cholera toxin B subunit fusion protein in transgenic potato. Mol. Biol. (2004) 28(1):33-40.
145. NORDONE SK, PEACOCK JW, KIRWAN SM, STAATS HF: Capric acid and hydroxypropylmethylcellulose increase the immunogenicity of nasally administered peptide vaccines. AIDS Res. Hum. Retroviruses (2006) 22(6):558-568.
146. JOSEPH A, ITSKOVITZ-COOPER N, SAMIRA S et al.: A new intranasal influenza vaccine based on a novel polycationic lipid - ceramide carbamoyl-spermine (CCS) I. Immunogenicity and efficacy studies in mice. Vaccine (2006) 24(18):3990-4006.
147. IVANOV AP, DRAGUNSKY EM, CHUMAKOV KM: 1,25-Dihydroxyvitamin d3 enhances systemic and mucosal immune responses to inactivated poliovirus vaccine in mice. J. Infect. Dis. (2006) 193(4):598-600.
148. BERGMANN KC, WALDMAN RH: Enhanced murine respiratory tract IgA antibody response to oral influenza vaccine when combined with a lipoidal amine (avridine). Int. Arch. Allergy Appl. Immunol. (1988) 87(3):334-335.
149. PENG XM, XIE DY, GU L et al.: Effect of exogenous epitopes of helper T lymphocyte on humoral immunity of HBV S gene DNA immunity. Zhonghua Yi. Xue. Za Zhi. (2003) 83(3):232-236.
150. + T-cell epitopes administered to non-human primates (Callithrix jacchus jacchus). Microbes Infect. (2006) 8(8):2130-2137.
151. NEUMANN F, WAGNER C, KUBUSCHOK B et al.: Identification of an antigenic peptide derived from the cancer-testis antigen NY-ESO-1 binding to abroad range of HLA-DR subtypes. Cancer Immunol. Immunother. (2004) 53(7):589-599.
152. ALEXANDER J, DEL GUERCIO MF, MAEWAL A et al.: Linear PADRE T helper epitope and carbohydrate B cell epitope conjugates induce specific high titer IgG antibody responses. J. Immunol. (2000) 164(3):1625-1633.
153. ALEXANDER J, SIDNEY J, SOUTHWOOD S et al.: Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides. Immunity (1994) 1(9):751-761.
154. RESSING ME, VAN DRIEL WJ, BRANDT RM et al.: Detection of T helper responses, but not of human papillomavirus-specific cytotoxic T lymphocyte responses, after peptide vaccination of patients with cervical carcinoma. J. Immunother. (2000) 23(2):255-266.
155. DAFTARIAN P, ALI S, SHARAN R et al.: Immunization with Th-CTL fusion peptide and cytosine-phosphate-guanine DNA in transgenic HLA-A2 mice induces recognition of HIV-infected T cells and clears vaccinia virus challenge. J. Immunol. (2003) 171(8):4028-4039.
156. DECROIX N, QUAN CP, PAMONSINLAPATHAM P, BOUVET JP: Mucosal immunity induced by intramuscular administration of free peptides in-line with PADRE: IgA antibodies to the ELDKWA epitope of HIV gp41. Scand. J. Immunol. (2002) 56(1):59-65.
157. PAMONSINLAPATHAM P, DECROIX N, MIHAILA-AMROUCHE L, BOUVET A, BOUVET JP: Induction of a mucosal immune response to the streptococcal M protein by intramuscular administration of a PADRE-ASREAK peptide. Scand. J. Immunol. (2004) 59(5):504-510.
158. ZHAO P, ZHAO LJ, CAO J, HONG HY, QI ZT: Enhancement of immune responses of hepatitis B virus core DNA vaccine by a signal Peptide and a universal helper T lymphocyte epitope. Sheng Wu Hua Xue. Ye Sheng Wu Wu Li Xue. Bao. (Shanghai) (2002) 34(3):341-346.
159. GUO CC, DING J, PAN BR et al.: Development of an oral DNA vaccine against MG7-Ag of gastric cancer using attenuated salmonella typhimurium as carrier. World J. Gastroenterol. (2003) 9(6):1191-1195.
160. UYTTENHOVE C, ARENDSE B, STROOBANT V, BROMBACHER F, VAN SNICK J: Development of an anti-IL-12 p40 auto-vaccine: protection in experimental autoimmune encephalomyelitis at the expense of increased sensitivity to infection. Eur. J. Immunol. (2004) 34(12):3572-3581.
161. MORAVEC T, SCHMIDT MA, HERMAN EM, WOODFORD-THOMAS T: Production of E. coli heat labile toxin (LT) B subunit in soybean seed and analysis of its immunogenicity as an oral vaccine. Vaccine (2007) 25(9):1647-1657.
162. MASON HS, HAQ TA, CLEMENTS JD, ARNTZEN CJ: Edible vaccine protects mice against E. coli heat-labile enterotoxin (LT): potatoes expressing a synthetic LT-B gene. Vaccine (1998) 16(13):1336-1343.
163. WEN SX, TEEL LD, JUDGE NA, O'BRIEN AD: A plant-based oral vaccine to protect against systemic intoxication by Shiga toxin type 2. Proc. Natl. Acad. Sci. USA (2006) 103(18):7082-7087.
164. LEE KY, KIM DH, KANG TJ et al.: Induction of protective immune responses against the challenge of Actinobacillus pleuropneumoniae by the oral administration of transgenic tobacco plant expressing ApxIIA toxin from the bacteria. FEMS Immunol. Med. Microbiol. (2006) 48(3):381-389.
165. WEBSTER DE, COONEY ML, HUANG Z et al.: Successful boosting of a DNA measles immunisation with an oral plant-derived measles virus vaccine. J. Virol. (2002) 76:7910-7912.
166. RIGANO MM, DREITZ S, KIPNIS AP, IZZO AA, WALMSLEY AM: Oral immunogenicity of a plant-made, subunit, tuberculosis vaccine. Vaccine (2006) 24:691-695.
167. LAMPHEAR BJ, JILKA JM, KESL L et al.: A corn-based delivery system for animal vaccines: an oral transmissible gastroenteritis virus vaccine boosts lactogenic immunity in swine. Vaccine (2004) 22(19):2420-2424.
168. SHCHELKUNOV SN, SALYAEV RK, POZDNYAKOV SG et al.: Immunogenicity of a novel, bivalent, plant-based oral vaccine against hepatitis B and human immunodeficiency viruses. Biotechnol. Lett. (2006) 28(13):959-967.
169. SASAGAWA T, TANI M, BASHA W et al.: A human papillomavirus type 16 vaccine by oral delivery of L1 protein. Virus Res. (2005) 110(1-2):81-90.
170. JHA RK, XU ZR, BAI SJ et al.: Protection of Procambarus clarkii against white spot syndrome virus using recombinant oral vaccine expressed in Pichia pastoris. Fish Shellfish Immunol. (2007) 2(4):295-307.
171. TAMARU Y, OHTSUKA M, KATO K et al.: Application of the arming system for the expression of the 380R antigen from red sea bream iridovirus (RSIV) on the surface of yeast cells: a first step for the development of an oral vaccine. Biol. Prog. (2006) 22(4):949-953.
172. GONG Z, JIN Y, ZHANG Y: Suppression of diabetes in non-obese diabetic (NOD) mice by oral administration of a cholera toxin B subunit-insulin B chain fusion protein vaccine produced in silkworm. Vaccine (2007) 25(8):1444-1451.
173. SISKIND GW, HOWARD JG: Studies on the induction of immunological unresponsiveness to pneumococcal polysaccharide in mice. J. Exp. Med. (1966) 124(3):417-429.
174. KAGNOFF MF: Oral tolerance. Ann. NY Acad. Sci. (1982) 392:248-265.
175. TACKET CO, MASON HS: A review of oral vaccination with transgenic vegetables. Microbes Infect. (1999) 1(10):777-783.
176. SILIN DS, LYUBOMSKA OV: Overcoming immune tolerance during oral vaccination against actinobacillus pleuropneumoniae. J. Vet. Med. B (2002) 49: 169-175.
177. FOSTER N, HIRST BH: Exploiting receptor biology for oral vaccination with biodegradable particulates. Adv. Drug Deliv. Rev. (2005) 57(3):431-450.
178. STEINMAN RM, HAWIGER D, LIU K et al.: Dendritic cell function in vivo during the steady state: a role in peripheral tolerance. Ann. NY Acad. Sci. (2003) 987:15-25.
179. TAKAGI H, HIROI T, YANG L et al.: A rice-based edible vaccine expressing multiple T cell epitopes induces oral tolerance for inhibition of Th2-mediated IgE responses. Proc. Natl. Acad. Sci. USA (2005) 10(48):17525-17530.
180. SAIF LJ: Coronavirus immunogens. Vet. Microbiol. (1993) 37(3-4):285-297.
181. SILIN DS, LYUBOMSKA OV, WENG CN: Mycoplasma hyopneumoniae vaccination influence on porcine reproductive and respiratory syndrome virus and mycoplasma hyopneumoniae coinfection. Acta Veterinaria Brn. (2001) 70:413-420.
182. BOURINBAIAR AS, JIRATHITIKAL V, METADILOGKUL O et al.: Phase II placebo-controlled study of V-1 Immunitor as a therapeutic modality for treatment of HIV. J. Clin. Virol. (2004) 31:S55-S62.
183. JIRATHITIKAL V, SOOKSATHAN P, METADILOGKUL O, BOURINBAIAR AS: V-1 Immunitor: oral therapeutic AIDS vaccine with prophylactic potential. Vaccine. (2003) 21:624-628.